Virtu Financial LLC purchased a new position in shares of Anavex Life Sciences Corp (NASDAQ:AVXL) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 49,580 shares of the biotechnology company’s stock, valued at approximately $152,000. Virtu Financial LLC owned 0.10% of Anavex Life Sciences as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the company. Deutsche Bank AG bought a new position in Anavex Life Sciences in the 4th quarter worth about $28,000. Edge Wealth Management LLC raised its holdings in shares of Anavex Life Sciences by 200.0% in the 1st quarter. Edge Wealth Management LLC now owns 30,000 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 20,000 shares in the last quarter. Hikari Power Ltd purchased a new stake in shares of Anavex Life Sciences in the 4th quarter valued at about $231,000. Tibra Equities Europe Ltd purchased a new stake in shares of Anavex Life Sciences in the 1st quarter valued at about $258,000. Finally, Geode Capital Management LLC raised its holdings in shares of Anavex Life Sciences by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 291,948 shares of the biotechnology company’s stock valued at $455,000 after acquiring an additional 3,687 shares in the last quarter. Institutional investors own 14.58% of the company’s stock.
Several analysts have weighed in on the company. ValuEngine raised Anavex Life Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Zacks Investment Research raised Anavex Life Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Finally, Roth Capital set a $10.00 price target on Anavex Life Sciences and gave the stock a “buy” rating in a research note on Friday, February 8th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $7.50.
Anavex Life Sciences stock traded down $0.10 during trading hours on Wednesday, reaching $3.60. The company had a trading volume of 467,674 shares, compared to its average volume of 330,567. The stock has a market capitalization of $176.57 million, a P/E ratio of -9.22 and a beta of 2.47. Anavex Life Sciences Corp has a 12-month low of $1.25 and a 12-month high of $4.35.
Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. As a group, sell-side analysts forecast that Anavex Life Sciences Corp will post -0.67 earnings per share for the current year.
Anavex Life Sciences Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Featured Story: What are no-load funds?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.